Citigroup
MDGL icon

Citigroup’s Madrigal Pharmaceuticals MDGL Stock Holding History

Citigroup’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.71M Hold
9,000
– – ﹤0.01% 2025
2025
Q4 		$5.24M Sell
9,000
-18,000
-67% -$9.19M ﹤0.01% 1974
2025
Q3 		$12.4M Buy
27,000
+500
+2% +$187K 0.01% 1346
2025
Q2 		$8.02M Sell
26,500
-13,500
-34% -$4.02M ﹤0.01% 1533
2025
Q1 		$13.2M Buy
40,000
+31,400
+365% +$10.3M 0.01% 1192
2024
Q4 		$2.65M Sell
8,600
-104,100
-92% -$29.3M ﹤0.01% 2574
2024
Q3 		$23.9M Buy
112,700
+50,100
+80% +$12.8M 0.01% 854
2024
Q2 		$17.5M Buy
+62,600
New +$14.9M 0.01% 947
2024
Q1 		– Sell
-5,000
Closed -$1.16M – 5771
2023
Q4 		$1.16M Hold
5,000
– – ﹤0.01% 2697
2023
Q3 		$730K Buy
5,000
+4,500
+900% +$847K ﹤0.01% 2767
2023
Q2 		$116K Hold
500
– – ﹤0.01% 4175
2023
Q1 		$121K Sell
500
-3,000
-86% -$817K ﹤0.01% 3946
2022
Q4 		$1.02M Buy
+3,500
New +$342K ﹤0.01% 2591
2022
Q3 		– Sell
-17,900
Closed -$1.28M – 6124
2022
Q2 		$1.28M Buy
+17,900
New +$1.32M ﹤0.01% 2424

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citigroup's MDGL Position: Q1 2026 in Review

Citigroup increased its Madrigal Pharmaceuticals (MDGL) stake by 9.7% in Q1 2026, buying an estimated $1.08M and bringing the position to 25,589 shares worth $13.4M. The position accounts for 0.01% of the portfolio, ranked #1294.

Citigroup first reported a position in MDGL in Q2 2013 and has held it in 48 quarters since. The position peaked at $30.3M in Q4 2024. 378 funds tracked by Wall St. Rank hold MDGL as of Q1 2026.

  • Citigroup held 25,589 shares of Madrigal Pharmaceuticals worth $13.4M as of Q1 2026.
  • Citigroup bought 2,262 Madrigal Pharmaceuticals shares in Q1 2026, an estimated $1.08M.
  • Madrigal Pharmaceuticals made up 0.01% of Citigroup's portfolio in Q1 2026, its #1294 holding.
  • Citigroup first reported a position in Madrigal Pharmaceuticals in Q2 2013 and has held it in 48 quarters since.
  • Citigroup's Madrigal Pharmaceuticals position peaked at $30.3M in Q4 2024.
  • 378 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.